Will Lester

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1816373/publications.pdf

Version: 2024-02-01

		471509	526287
30	2,324	17	27
papers	citations	h-index	g-index
30	30	30	2280
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	AAV5–Factor VIII Gene Transfer in Severe Hemophilia A. New England Journal of Medicine, 2017, 377, 2519-2530.	27.0	529
2	Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood, 2007, 109, 112-121.	1.4	364
3	Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A. New England Journal of Medicine, 2020, 382, 29-40.	27.0	316
4	The diagnosis and management of von <scp>W</scp> illebrand disease: a <scp>U</scp> nited <scp>K</scp> ingdom <scp>H</scp> aemophilia <scp>C</scp> entre <scp>D</scp> octors <scp>O</scp> rganization guideline approved by the <scp>B</scp> ritish <scp>C</scp> ommittee for <scp>S</scp> tandards in <scp>H</scp> aematology. British Journal of Haematology, 2014, 167, 453-465.	2.5	297
5	Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology. Gut, 2020, 69, 1382-1403.	12.1	172
6	Identification and characterization of a novel P2Y12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study. Blood, 2009, 113, 4110-4113.	1.4	67
7	Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A. Haemophilia, 2021, 27, 947-956.	2.1	62
8	Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update. Gut, 2021, 70, 1611-1628.	12.1	61
9	Expression of 14 von Willebrand factor mutations identified in patients with typeÂ1 von Willebrand disease from the MCMDM-1VWD study. Journal of Thrombosis and Haemostasis, 2009, 7, 1304-1312.	3.8	57
10	Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012 (⟨i⟩Br. J. ⟨ i⟩⟨i⟩ Haematol⟨ i⟩⟨i⟩⟨i⟩⟩ 2012; 157: 47–58): use of direct acting oral anticoagulants. British Journal of Haematology, 2020, 189, 212-215.	2.5	53
11	Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A. Nature Medicine, 2022, 28, 789-797.	30.7	48
12	Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update. Endoscopy, 2021, 53, 947-969.	1.8	47
13	Fatal venous thromboembolism associated with hospital admission: a cohort study to assess the impact of a national risk assessment target. Heart, 2013, 99, 1734-1739.	2.9	46
14	Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline. Haemophilia, 2020, 26, 151-155.	2.1	44
15	Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: A United Kingdom Haemophilia Centre Doctors' Organisation guideline. Haemophilia, 2020, 26, 6-16.	2.1	31
16	The prevalence of the cysteine1584 variant of von Willebrand factor is increased in type 1 von Willebrand disease: coâ€segregation with increased susceptibility to ADAMTS13 proteolysis but not clinical phenotype. British Journal of Haematology, 2005, 128, 830-836.	2.5	28
17	Outcomes of pregnancy in patients with known Budd-Chiari syndrome. World Journal of Hepatology, 2017, 9, 945.	2.0	21
18	Natural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis. Blood, 2022, 139, 2553-2560.	1.4	20

#	Article	IF	CITATIONS
19	Intracranial hemorrhage in immune thrombotic thrombocytopenic purpura treated with caplacizumab. Journal of Thrombosis and Haemostasis, 2021, 19, 1922-1925.	3.8	10
20	Investigation of the contribution of an underlying platelet defect in women with unexplained heavy menstrual bleeding. Platelets, 2019, 30, 56-65.	2.3	9
21	A United Kingdom Immune Thrombocytopenia (<scp>ITP</scp>) Forum review of practice: thrombopoietin receptor agonists. British Journal of Haematology, 2018, 180, 591-594.	2.5	7
22	Varicose Veins and Deep Venous Thrombosis. JAMA - Journal of the American Medical Association, 2018, 320, 509.	7.4	7
23	Laboratory coagulation tests and recombinant porcine factor VIII: A United Kingdom Haemophilia Centre Doctors' Organisation guideline. Haemophilia, 2022, 28, 515-519.	2.1	7
24	NICE NG89 recommendations for extended pharmacological thromboprophylaxis – is it justified and is it cost effective: a rebuttal from the British Society for Haematology. British Journal of Haematology, 2019, 186, 790-791.	2.5	6
25	Liver graft outcomes from donors with vaccine induced thrombosis and thrombocytopenia (VITT): United Kingdom multicenter experience. American Journal of Transplantation, 2022, 22, 996-998.	4.7	6
26	Management of acute myocardial infarction in a patient with idiopathic thrombocytopenic purpura, the value of optical coherence tomography: a case report. European Heart Journal - Case Reports, 2020, 4, 1-5.	0.6	5
27	Are we assessing venous thromboembolism (VTE) risk appropriately for hospitalised medical patients? The National VTE Risk Assessment Tool versus Padua Prediction Score. British Journal of Haematology, 2020, 189, e16-e18.	2.5	4
28	Thromboprophylaxis for the Obese Surgical Patient. , 0, , 181-185.		0
29	Coronary artery thrombus resulting in ST-elevation myocardial infarction in a patient with COVID-19. BMJ Case Reports, 2021, 14, e243811.	0.5	0
30	Pitfalls in laboratory monitoring of treatment in people with Haemophilia. Blood Reviews, 2022, 55, 100946.	5.7	0